Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[11C]PBR28
- Development stage
- Unknown
- Lead developer
- National Institute of Mental Health
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[11C]PBR28 is a carbon-11 radiolabeled small molecule PET radioligand developed by the National Institute of Mental Health (NIMH). It specifically targets the 18-kDa translocator protein (TSPO), formerly known as the peripheral benzodiazepine receptor (PBR). TSPO is expressed at low levels in the healthy central nervous system but is significantly upregulated in activated microglia and astrocytes during neuroinflammation. [11C]PBR28 was designed as a high-affinity alternative to the first-generation tracer [11C]PK11195, offering improved signal-to-noise ratios and superior specific binding. It is used as a diagnostic imaging tool in clinical research to quantify neuroinflammation across various conditions, including Alzheimer's disease, multiple sclerosis, Parkinson's disease, and traumatic brain injury.
- Other names
- N-acetyl-N-(2-[11C]methoxybenzyl)-2-phenoxy-5-pyridinamine[(11)C] PBR28
02
Targets
TSPO (Translocator Protein (18 kDa))
Beyond the preview
Go deeper on [11C]PBR28.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [11C]PBR28.